雄激素抑制联合选择性淋巴结及剂量递增放疗(ASCENDE-RT试验):低剂量率近距离放疗推量与剂量递增外照射推量治疗中高危前列腺癌的随机试验生存终点分析
ASCENDE-RT随机试验纳入398例中高危前列腺癌患者,随机接受12个月雄激素剥夺治疗+盆腔放疗46 Gy后,分别采用低剂量率前列腺近距离放疗推量或剂量递增外照射推量至78 Gy。中位随访6.5年,低剂量率近距离放疗推量组生化失败风险显著低于外照射推量组,但两组总生存无显著差异。
要点
- 低剂量率近距离放疗推量组生化失败风险约为外照射推量组的一半(MVA HR 2.04)。
- 9年生化无进展生存率:低剂量率近距离放疗推量组83%,外照射推量组62%。
- 两组总生存无显著差异(MVA HR 1.13;P=.62)。
核心结论
- 与78 Gy外照射推量相比,低剂量率前列腺近距离放疗推量在中位随访6.5年时使生化失败风险减半。
- 尽管生化失败与死亡率增加相关,但两组总生存无显著差异。
研究设计与样本
- ASCENDE-RT为随机试验,纳入398例中高危前列腺癌患者,中位年龄68岁,69%(n=276)为高危。
- 患者随机接受标准臂(12个月雄激素剥夺治疗+盆腔放疗46 Gy+剂量递增外照射推量至78 Gy,n=200)或实验臂(以低剂量率前列腺近距离放疗推量替代外照射推量,n=198)。
- 中位随访6.5年。
主要发现
- 在意向治疗分析中,随机分配至剂量递增外照射推量组的患者生化失败可能性是低剂量率近距离放疗推量组的两倍(多变量分析HR 2.04;P=.004)。
- 5年、7年和9年生化无进展生存率Kaplan-Meier估计值:低剂量率近距离放疗推量组分别为89%、86%和83%,外照射推量组分别为84%、75%和62%(log-rank P<.001)。
- 低剂量率近距离放疗推量使中危和高危患者均获益。
- 多变量分析中,与总生存降低相关的变量仅为年龄(HR 1.06/年;P=.004)和生化失败(HR 6.30;P<.001)。
- 两组总生存无显著差异(多变量分析HR 1.13;P=.62)。
临床怎么用
- 对于中高危前列腺癌患者,在12个月雄激素剥夺治疗和盆腔放疗46 Gy基础上,低剂量率前列腺近距离放疗推量较剂量递增外照射推量至78 Gy可显著改善生化无进展生存。
- 临床决策时需权衡生化控制获益与总生存无显著差异的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the primary endpoint of biochemical progression-free survival (b-PFS) and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 methods of dose escalation for intermediate- and high-risk prostate cancer. METHODS AND MATERIALS: ASCENDE-RT enrolled 398 men, with a median age of 68 years; 69% (n=276) had high-risk disease. After stratification by risk group, the subjects were randomized to a standard arm with 12 months of androgen deprivation therapy, pelvic irradiation to 46 Gy, followed by a dose-escalated external beam radiation therapy (DE-EBRT) boost to 78 Gy, or an experimental arm that substituted a low-dose-rate prostate brachytherapy (LDR-PB) boost. Of the 398 trial subjects, 200 were assigned to DE-EBRT boost and 198 to LDR-PB boost. The median follow-up was 6.5 years. RESULTS: In an intent-to-treat analysis, men randomized to DE-EBRT were twice as likely to experience biochemical failure (multivariable analysis [MVA] hazard ratio [HR] 2.04; P=.004). The 5-, 7-, and 9-year Kaplan-Meier b-PFS estimates were 89%, 86%, and 83% for the LDR-PB boost versus 84%, 75%, and 62% for the DE-EBRT boost (log-rank P<.001). The LDR-PB boost benefited both intermediate- and high-risk patients. Because the b-PFS curves for the treatment arms diverge sharply after 4 years, the relative advantage of the LDR-PB should increase with longer follow-up. On MVA, the only variables correlated with reduced overall survival were age (MVA HR 1.06/y; P=.004) and biochemical failure (MVA HR 6.30; P<.001). Although biochemical failure was associated with increased mortality and randomization to DE-EBRT doubled the rate of biochemical failure, no significant overall survival difference was observed between the treatment arms (MVA HR 1.13; P=.62). CONCLUSIONS: Compared with 78 Gy EBRT, men randomized to the LDR-PB boost were twice as likely to be free of biochemical failure at a median follow-up of 6.5 years.
引用
- Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28262473. doi:10.1016/j.ijrobp.2016.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。